Finance

Beta
Lists
096530:KOSDAQ
Seegene Inc
â‚©27,350.00
-8.38%
(-2,500.00) 1D
Jun 8, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 096530...
Open
â‚©28,000
High
â‚©28,700
Low
â‚©26,950
Mkt. cap
1.43T
Avg. vol.
473.07K
Volume
326.64K
Dividend
4.02%
Quarterly dividend
â‚©275
Ex-dividend date
Jun 29, 2026
P/E ratio
23.29
52-wk high
â‚©35,700
52-wk low
â‚©21,700
EPS
â‚©1,174
Shares outstanding
52.23M
No. of employees
215
Open
â‚©28,000
High
â‚©28,700
Low
â‚©26,950
Mkt. cap
1.43T
Avg. vol.
473.07K
Volume
326.64K
Dividend
4.02%
Quarterly dividend
â‚©275
Ex-dividend date
Jun 29, 2026
P/E ratio
23.29
52-wk high
â‚©35,700
52-wk low
â‚©21,700
EPS
â‚©1,174
Shares outstanding
52.23M
No. of employees
215
News stories
From sources across the web
Profile
Seegene, Inc is a Korean manufacturer of in vitro diagnostic products, particularly molecular diagnostics. Its portfolio includes a range of assays and screening products for sepsis, respiratory diseases such as influenza and respiratory syncytial virus, as well as sexually transmitted infections. It was founded in 2000. In early 2020, it began developing and distributing a range of tests for SARS-CoV-2, the virus that causes COVID-19. Along with its headquarters in Seoul, South Korea, the company has subsidiaries in the U.S., Canada, Germany, Italy, Mexico, Brazil, and the Middle East. In September 2010, Seegene undertook a $16.6 million initial public offering to list on KOSDAQ, a trading board of Korea Exchange. Wikipedia
About Seegene Inc
CEOJong Yun Cheon
Employees215
FoundedSep 16, 2000
Headquarters-
SectorBiotechnology
Websiteseegene.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
114.06B
113.54B
130.63B
129.14B
Cost of goods sold
44.84B
42.43B
45.81B
42.45B
Cost of revenue
44.84B
42.43B
45.81B
42.45B
Research and development expenses
17.58B
15.06B
17.64B
13.70B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39.97B
38.79B
51.71B
40.98B
Operating expense
66.08B
61.51B
77.88B
63.14B
Total operating expenses
110.91B
103.93B
123.68B
105.59B
Operating income
3.15B
9.61B
6.95B
23.55B
Other non operating income
118.69M
-422.91M
2.31B
447.44M
EBT including unusual items
-798.31M
18.50B
15.20B
39.32B
EBT excluding unusual items
-3.63B
20.32B
20.82B
41.11B
Income tax expense
-726.90M
3.89B
10.21B
4.57B
Effective tax rate
91.05%
21.05%
67.19%
11.63%
Other operating expenses
-
-
-
-
Net income
-122.00M
14.56B
4.94B
34.73B
Net profit margin
-0.11%
12.82%
3.78%
26.89%
Earnings per share
-
-
-
-
Interest and investment income
3.77B
2.47B
4.81B
2.50B
Interest expense
-1.25B
-1.31B
-603.99M
-936.74M
Net interest expenses
2.52B
1.16B
4.21B
1.57B
Depreciation and amortization charges
7.11B
7.14B
7.29B
7.93B
EBITDA
20.98B
26.99B
24.01B
40.12B
Gain or loss from assets sale
-39.82M
85.78M
121.04M
9.05M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer